AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Vivani Medical Secures $10M Equity Financing, Reports Q2 2025 Financials, and Plans Rapid Advancement of Semaglutide Implant NPM-139.
ByAinvest
Wednesday, Aug 13, 2025 4:20 pm ET1min read
Vivani Medical reported Q2 2025 financial results and provided a business update, including a $10M equity financing to accelerate development of NPM-139, a semaglutide implant for weight loss. The company plans to advance NPM-139 following positive preclinical data and promising results from the LIBERATE-1 Phase 1 clinical study of NPM-115. Vivani will also spin off Cortigent, a division developing brain implant devices.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet